The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
Canaccord Genuity has downgraded Pliant (PLRX) to hold following news that the company has paused a clinical trial for its ...
Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback